Background
==========

Gastric cancer is the second most common cancer and the third leading cause of cancer-related death in China \[[@B1]-[@B3]\]. It remains very difficult to cure effectively, primarily because most patients present with advanced diseases \[[@B4]\]. Therefore, how to recognize and track or kill early gastric cancer cells is a great challenge for early diagnosis and therapy of patients with gastric cancer.

We have tried to establish an early gastric cancer pre-warning and diagnosis system since 2005 \[[@B5],[@B6]\]. We hoped to find early gastric cancer cells *in vivo* by multi-mode targeting imaging and serum biomarker detection techniques \[[@B7]-[@B12]\]. Our previous studies showed that subcutaneous and *in situ* gastric cancer tissues with 5 mm in diameter could be recognized and treated by using multi-functional nanoprobes such as BRCAA1-conjugated fluorescent magnetic nanoparticles \[[@B13]\], her2 antibody-conjugated RNase-A-associated CdTe quantum dots \[[@B14]\], folic acid-conjugated upper conversion nanoparticles \[[@B15],[@B16]\], RGD-conjugated gold nanorods \[[@B17]\], ce6-conjugated carbon dots \[[@B18]\], ce6-conjugated Au nanoclusters (Au NCs) \[[@B19],[@B20]\]. However, the clinical translation of these prepared nanoprobes still exists as a great challenge because no one kind of biomarker is specific for gastric cancer. Looking for new potential biomarker of gastric cancer and development of safe and effective nanoprobes for targeted imaging and simultaneous therapy of *in vivo* early gastric cancer have become our concerns.

Dr. Jian Ni et al. found that the α-subunit of ATP synthase exhibited over-expression in breast cancer cell lines such as MCF-7H and MCF-7 cell line, with different metastasis potentials, and also exhibited high expression in breast cancer tissues, hepatocellular carcinoma, colon cancer, and prostate cancer \[[@B21]\]. ATP synthase is responsible for ATP production in oxidative phosphorylation and can work in reverse as a proton-pumping ATPase \[[@B22],[@B23]\]. ATP synthase expression is localized exclusively in the mitochondria where it generates most cellular ATP. However, ATP synthase components have recently been identified as cell-surface receptors for apparently unrelated ligands in the course of studies carried out on angiogenesis \[[@B24]-[@B26]\], lipoprotein metabolism \[[@B27]\], innate immunity \[[@B28]-[@B32]\], etc. by immunofluorescence, biochemistry, and proteomics analyses. Its molecular mechanism, function, and significance have not been clarified well.

Dr. Jian Ni\'s group prepared specific monoclonal antibody against the α-subunit of ATP synthase, named as HAI-178 antibody, and provided this to my group. Our primary studies showed that the α-subunit of ATP synthase also exhibited over-expression in gastric cancer cells and clinical gastric cancer tissues, with no or very low expression in normal gastric mucous tissues. Especially as one kind of self antibody which existed in human sera from patients with gastric cancer, this should be a potential biomarker with diagnosis value. In our previous work, we prepared fluorescent magnetic nanoparticles (FMNPs) composed of silicon-wrapped magnetic nanoparticles and CdTe quantum dots and used FMNPs-labeled MSC cells to realize the targeted imaging and hyperthermia therapy of *in vivo* gastric cancer \[[@B33]\]. We also confirmed that the prepared fluorescent magnetic nanoparticles show good biocompatibility \[[@B34]\].

In the present study, we fully used the advantages of FMNPs and potential gastric cancer biomarker α-subunit of ATP synthase, prepared HAI-178 monoclonal antibody-conjugated FMNPs, and investigated the feasibility of prepared nanoprobes to target *in vitro* and *in vivo* gastric cancer cells. Our results show that as-prepared nanoprobes can be used for *in vivo* dual-model imaging and therapy of *in vivo* cancer, and have great potential in applications such as dual-model imaging and simultaneous therapy of early gastric cancer in the near future.

Methods
=======

All animal experiments (no. SYXK2007-0025) were approved by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University.

Expression of α-subunit of ATP synthase in gastric cancer tissues
-----------------------------------------------------------------

HAI-178 monoclonal antibody was presented as a gift by Dr. Jian Ni. HAI-178 monoclonal antibody was used as first antibody to stain 172 specimens of gastric cancer and control gastric mucous tissues with immunohistochemistry method \[[@B35]\], which were collected from Xi'an Central Hospital, Xianya Hospital, Changzheng Hospital, and the First People\'s Hospital in Shanghai, and identified by pathological examination.

Preparation and Surface functionalization of FMNPs
--------------------------------------------------

FMNPs were prepared according to our previous report \[[@B36]-[@B38]\]. Before coupling the FMNPs with the HAI-178 antibody, we first functionalized the surface functional group of FMNPs as carboxyl group. Solutions of 95 mL ethanol and 2 mL 3-aminopropyltriethoxysilane (APS) were added to form a mixed solution and allowed to react at room temperature for 24 h. The aminosilane-modified FMNPs were separated by permanent magnet and were washed with deionized water three times then redispersed the FMNPs-NH~2~ in 100 mL dimethylformamide (DMF) and added with excess succinic anhydride to form a mixed solution and react at room temperature for 24 h. The carboxyl-modified FMNPs were separated by permanent magnet again and washed with deionized water three times.

Preparation and characterization of HAI-178 monoclonal antibody-conjugated FMNPs
--------------------------------------------------------------------------------

We used a two-step process to obtain stable HAI-178-antibody-FMNPs conjugation. Solution of 1.5 mg FMNPs-COOH was dispersed in 2 mL pH 7 PBS buffer and was sonicated for 10 min. Then we mixed 1 mL of fresh 400 mM EDC and 100 mM NHSS in pH 6.0 MES buffer and rotated it at room temperature for 15 min. After this, the resulting solution was separated by magnetic field, and 1 mg/mL of HAI-178 monoclonal antibody was added to the above mixture and stirred in dark place for 2 h. To remove free HAI-178 antibody, the residual reaction mixture was separated by magnetic field and the solid remaining was washed with 1 mL of PBS buffer three times. Finally, 1 mL of 0.05% Tween-20/PBS was added to the HAI-178 antibody-FMNPs conjugation and the bioconjugation was stored at 4°C. When used, this HAI-178 antibody-FMNPs conjugation should be diluted with PBS/0.05% Tween-20. Then we used the Nano Drop device to quantify the coupling rate of HAI-178 antibody with FMNPs-COOH. Before the coupling reaction, we measured the total concentration of HAI-178 antibody. After the coupling reaction, we measured the HAI-178 antibody concentration in residual reaction mixture and calculated the coupling rate according the equation:

Coupling (%) = (1 − Concentration of HAI-178 antibody in residual reaction mixture/Total concentration of HAI-178 antibody) × 100. The as-prepared nanoprobes and pure FMNPs were characterized by transmission electron microscopy, photoluminescence (PL) spectrometry, and fluorescent microscopy.

Nanoprobes for *in vitro* targeting imaging of gastric cancer cells
-------------------------------------------------------------------

Gastric cancer cell line MGC803 cells with over-expression of α-subunit of ATP synthase were used as target cells, and human gastric mucous GES-1 cells without expression of α-subunit of ATP synthase was used as control. The cells were cultured and collected, then were treated with 50 μg/mL HAI-178 antibody-conjugated FMNPs nanoprobes, and cultured in a humidified 5% CO~2~-balanced air incubator at 37°C for 4 h. Meanwhile, the MGC803 and GES-1 cells were treated with FMNPs as the control group. Afterward, the cells were rinsed with PBS three times, and then the cells were fixed with 2.5% glutaraldehyde solution for 30 min. For nuclear counterstaining, MGC803 cells were incubated with 1 mM Hoechst 33258 (Invitrogen, Life Technologies, Carlsbad, CA, USA) in PBS for 5 min. The cells were observed and imaged using fluorescence microscope (Nikon TS100-F, Nikon Instruments, Shanghai, China).

Nanoprobes for fluorescence imaging of gastric cancer-bearing nude mice
-----------------------------------------------------------------------

Animal experiments were performed according to Guidelines for Animal Care and Use Committee, Shanghai Jiao Tong University. Male athymic nude mice were obtained from Shanghai LAC Laboratory Animal Co. Ltd., Chinese Academy of Sciences (Shanghai, China). MGC803 cells (1 × 10^6^) were injected subcutaneously into the right anterior flank area of the male nude mice with 4 to 5 weeks of age. The tumors were allowed to grow to a diameter of approximately 5 mm. At that point, about 40 μg HAI-178 antibody-FMNPs nanoprobes was injected into the mice (*n* = 3) via the tail vein. Mice were respectively monitored in a non-invasive manner at 0.5, 1, 3, 6, and 12 h to get fluorescence images. Then, tumor and major organs were collected, were placed on black papers, and subjected to IVIS Lumina imaging system (Xenogen) with emission wavelengths of 630 nm. The fluorescence images were acquired, and the total fluorescence flux for each sample was obtained. For the control experiment, mice (*n* = 3) were injected via tail vein with 40 μg of FMNPs and subjected to optical imaging at various time points post-injection. Identical illumination settings (e.g., lamp voltage, filter, exposure time) were used in all animal imaging experiments.

Nanoprobes for MRI and fluorescent imaging of gastric cancer-bearing nude mice
------------------------------------------------------------------------------

For MR imaging, gastric MGC803 cells (1 × 10^6^) were injected subcutaneously into the right anterior flank area of male nude mice (*n* = 3) with 4 to 5 weeks of age. After the tumors reached approximately 5 mm in diameter, mice were injected with the HAI-178 antibody-FMNPs nanoprobes. MR imaging was performed at 6 h post-injections on animals anesthetized with 0.4% pentobarbital, using 3.0 T field intensity by GE HDX 3.0 T MR imaging instrument (GE Healthcare, Beijing, China) equipped with GE Signal Excite 3.0 T magnetic resonance imaging (MRI) software. The imaging protocol consisted of coronal and transverse T2-weighted spin echo (SE) pulse sequences. To produce T2 maps, the following imaging parameters were used: TR/TE = 1,000/10, 20, 30, 40, 40, 50, 60, 70, 80 ms; FOV = 8.0 cm; NEX = 1; slice thickness = 2.0 mm; number of excitations = 2. MR imaging was performed on the mice (*n* = 3) model with gastric tumor, and injected FMNPs without labeling HAI-178 antibody were used for the negative control. Then, the mice models with gastric cancer were injected with 40 μg HAI-178--FMNPs via the tail vein and imaged by small animal imaging system at 6 h post-injection \[[@B13]\].

Nanoprobes for integrated therapy of *in vivo* gastric cancer
-------------------------------------------------------------

Gastric cancer-bearing mice were randomly divided into four groups: test group 1 (10 mice) (200 μg of HAI-178-FMNPs plus external alternating magnetic field with 63 kHz and 7 kA/m for 4 min), test group 2 (10 mice) (200 μg of FMNPs plus external alternating magnetic field with 63 kHz and 7 kA/m for 4 min), test group 3 (10 mice) (100 μg of HAI-178 antibody), and blank control (5 mice) (saline). Every 2 days, the mice sizes were measured up to 14 days, then the mice were sacrificed.

Effects of HAI-178-FMNPs on important organs
--------------------------------------------

The mice in test group were sacrificed after *in vivo* imaging. For histological evaluation, excised important organs from the heart, liver, spleen, lung, and kidney were frozen and embedded by medium at −20°C, were sectioned into 8-μm slices, were stained by hematoxylin and eosin (HE) stain method, and were observed by microscopy.

Statistical analysis
--------------------

Each experiment was repeated three times in duplicate. The results were presented as mean ± SD. Statistical differences were evaluated using the *t-*test and considered significance at *P* \< 0.05.

Results and discussion
======================

Expression of α-subunit of ATP synthase in gastric cancer tissues
-----------------------------------------------------------------

Figure [1](#F1){ref-type="fig"}A showed the positive expression of α-subunit of ATP synthase in gastric cancer tissues; Figure [1](#F1){ref-type="fig"}B showed the negative expression of α-subunit of ATP synthase in gastric mucous tissues. We investigated the expression of α-subunit of ATP synthase in 172 specimens of gastric cancer tissues by immunohistochemistry method. As shown in Table [1](#T1){ref-type="table"}, α-subunit of ATP synthase exhibited over-expression in 94.7% of the gastric cancer tissues. In no or very low expression in normal gastric mucous tissues, there existed a statistical difference between two groups (*P* \< 0.01). We also observed that the expression of α-subunit of ATP synthase is not associated with patient\'s age (*P* \> 0.05) and positive lymph node and invasion (*P* \> 0.05). However, it is positively associated with the size of tumor (*P* \< 0.05), pathological grade (*P* \< 0.05), and TNM stage (*P* \< 0.05). This result highly suggests that α-subunit of ATP synthase may be a potential biomarker for most gastric cancer patients and may be very valuable for diagnosis and therapy of clinical gastric cancer patients.

![**Expression of α-subunit of ATP synthase in gastric cancer tissues and gastric mucous tissues (×50). (A)** Positive expression in gastric cancer tissues. **(B)** Negative expression in normal gastric mucous tissues.](1556-276X-9-274-1){#F1}

###### 

Clinicopathological data and ATP synthase α-subunit expression in 172 gastric cancers

                        **Description**    **α-ATP synthase expression**   **Total**    ***P*value**              
  --------------------- ----------------- ------------------------------- ------------ -------------- ----------- -----------------
  Age                   \<50                         5 (6.8%)              31 (42.4%)    37 (50.6%)    73 (100%)   Not significant
  ≥50                   4 (4.0%)                    32 (32.3%)             63 (63.6%)    99 (100%)                
  Size                  \<2 cm                       2 (11.7%)             11 (64.7%)    4 (23.5%)     17 (100%)     *P* \< 0.05
  ≥2 cm                 2 (3.4%)                    22 (37.9%)             31 (53.4%)    58 (100%)                
  Histological grade    Well                         3 (11.5%)             12 (46.1%)    11 (42.3%)    26 (100%)     *P* \< 0.05
  Moderate              7 (6.0%)                    43 (37.0%)             66 (56.8%)    116 (100%)               
  Poor                  0 (0.0%)                     3 (15.0%)             17 (85.0%)    20 (100%)                
  TNM stage             I                            2 (18.1%)             5 (45.4%)     4 (36.3%)     11 (100%)     *P* \< 0.05
  II                    2 (4.3%)                    25 (54.3%)             19 (41.3%)    46 (100%)                
  III                   0 (0%)                       3 (23.1)              10 (76.9%)    13 (100%)                
  Lymph node invasion   Positive                     3 (5.6%)              19 (35.8)     31 (58.4)     53 (100%)   Not significant
  Negative              2 (4.5%)                    13 (29.5%)             31 (70.4%)    44 (100%)                

Preparation and characterization of HAI-178-FMNPs nanoprobes
------------------------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}A, prepared FMNPs were composed of silica-wrapped CdTe and magnetic nanoparticles, and their sizes were 50 nm or so in diameter. As shown in Figure [2](#F2){ref-type="fig"}B, after FMNPs were conjugated with HAI-178 antibody, the as-prepared nanoprobes\' photoluminescence (PL) intensity was lower than that of FMNPs, exhibiting a left shift of 40 nm, which was due to the decrease in the polarization rate of the surrounding molecules, resulting in the decrease of stokes displacement and finally resulting in a blue shift in the emission spectra. Figure [2](#F2){ref-type="fig"}C showed that prepared FMNPs exhibited green color. Figure [2](#F2){ref-type="fig"}D showed that the magnesium intensity of as-prepared FMNPs and magnetic nanoparticles was 3.21 emu/g.

![**Characterization of FMNPs and HAI-178-FMNPs. (A)** HR-TEM of FMNPs. **(B)** PL spectra of FMNPs and HAI-178-FMNPs. **(C)** Fluorescent image of prepared FMNPs. **(D)** Magnesium of FMNPs and magnetic nanoparticles](1556-276X-9-274-2){#F2}

In the course of preparing HAI-178 antibody-FMNPs nanoprobes, we found that the surface functionalization of FMNPs was very the key to conjugate HAI-178 antibody with FMNPs via covalent bond. We observed that carboxyl groups on the surface of FMNPs conjugated with HAI-178 antibody easier than amino groups on the surface of FMNPs. In our experiment, the average coupling rate of HAI-178 antibody with FMNPs-COOH was 80.29%.

Nanoprobes for targeting *in vitro* gastric cancer cells
--------------------------------------------------------

The targeting ability of as-prepared nanoprobes *in vitro* was observed by fluorescence microscope. As shown in Figure [3](#F3){ref-type="fig"}A, HAI-178-conjugated FMNPs existed around MGC803 cellular membrane. HAI-178 antibody-FMNPs nanoprobes could enter into the cytoplasm of MGC803 cells after 4 h incubation with MGC803 cells, but not inside the nucleus, which highly suggests that HAI-178 antibody-conjugated FMNPs can target MGC803 cells specifically.

![**Fluorescent microscope observation of HAI-178-FMNPs bound to surface of MGC803 cells. (A)** HAI-178-FMNPs combined to the surface of MGC803 cell membrane (×10); inset is the magnified image (×100). **(B)** HAI-178-FMNPs bound to the membrane of MGC803 cells, blue nucleus (DAPI staining) (×10).](1556-276X-9-274-3){#F3}

Nanoprobes for fluorescent imaging of *in vivo* gastric cancer cells
--------------------------------------------------------------------

To evaluate the tumor-targeting properties of HAI-178 antibody-conjugated FMNPs nanoprobes, MGC803 cells-bearing nude mice models were prepared and monitored under a non-invasive manner for 12 h by using IVIS fluorescence imaging system. Figure [4](#F4){ref-type="fig"}A showed the nude mouse loaded with MGC803 gastric cancer cells. Figure [4](#F4){ref-type="fig"}B showed the strong fluorescent signal in the tumor site of gastric cancer-bearing nude mouse at 12 h post-injection. Figure [4](#F4){ref-type="fig"}C showed that strong fluorescent signals only existed in the tumor site of gastric cancer-bearing nude mouse. These results indicated that the HAI-178 antibody-conjugated FMNPs were preferentially accumulated in the tumor tissues and highly suggest that prepared nanoprobes can target efficiently tumor tissues inside gastric cancer-bearing nude mice.

![**Fluorescent imaging of gastric cancer-bearing nude mouse via tail vein injection with HAI-178-FMNPs by animal imaging system. (A)** Nude mouse loaded with gastric cancer. **(B)** Fluorescent imaging of the tumor site. **(C)** Overlay picture of gastric cancer-bearing nude mouse and fluorescent imaging of the tumor site.](1556-276X-9-274-4){#F4}

Nanoprobes for MR imaging of gastric cancer-bearing nude mice
-------------------------------------------------------------

*In vivo* MR imaging was performed on nude mice loaded with subcutaneous gastric cancer at 12 h post-injection. Representative images of T2 maps were shown in Figure [5](#F5){ref-type="fig"}. Figure [5](#F5){ref-type="fig"}A showed MR image of the nude mouse loaded with gastric cancer at longitudinal section, with circle showing the tumor site; a significant change in signal intensity was observed in site of tumor, indicating that there existed accumulation of the nanoprobes in the tumor site as shown in Figure [5](#F5){ref-type="fig"}B, showing the MR image of nude mouse at transverse direction. Our result showed that prepared nanoprobes can be used for targeted MR imaging of *in vivo* gastric cancer.

![**MRI image of gastric cancer-bearing nude mouse. (A)** MRI image of nude mouse at longitudinal direction; circle shows tumor site. **(B)** MRI image of nude mice at horizontal direction; circle shows the tumor site.](1556-276X-9-274-5){#F5}

Nanoprobes for therapy of gastric cancer-bearing nude mice
----------------------------------------------------------

As shown in Figure [6](#F6){ref-type="fig"}, the tumor tissues in control group (treated with saline) grew very quick, and the relative tumor volume became bigger and bigger as the feeding day increased. In the test group treated with FMNPs, under external alternating magnetic field with 63 kHz and 7 kA/m for 4 min, the tumor tissues in gastric cancer-bearing mice grew slower than the mice in control group. In the test group treated with HAI-178 antibody, the tumor tissues grew slower, which highly showed that HAI-178 could inhibit the growth of gastric cancer *in vivo*, similar to the inhibition of growth of breast cancer *in vivo*\[[@B26]\]. In test group HAI-178-FMNPs, the tumor tissues grew slowest, which highly indicate that the prepared HAI-178-FMNPs have a therapeutic function for gastric cancer *in vivo*. Compared with the control group, a statistical difference existed between two groups (*P* \< 0.05). Our results showed that the prepared HAI-178-conjugated FMNPs have a therapeutic function.

![Relative tumor volume of nude mice under different treated condition.](1556-276X-9-274-6){#F6}

Pathological analysis of important organs
-----------------------------------------

As shown in Figure [7](#F7){ref-type="fig"}, we used HE staining to check important organs including the heart, liver, spleen, lung and kidney, and no obvious damages were observed, which indirectly suggest that the prepared HAI-178-FMNPs nanoprobes did not damage important organs, showing good biocompatibility.

![HE staining of important organs such as the heart, liver, spleen, kidney, and lung.](1556-276X-9-274-7){#F7}

Potential mechanism of targeting imaging and therapy of gastric cancer
----------------------------------------------------------------------

In recent years, with the development of 'omics,' systems biology, and molecular imaging, a tendency of integration of multi-modality, multi-target imaging, and theranostic agents has emerged as a hotspot, a new concept called as 'systems molecular imaging' was suggested by Dr. Shen, which can be used to show the complexity, diversity, and *in vivo* biological behavior and the development and progress of disease in an organism qualitatively and quantitatively at a systems level. Ultimately, system molecular imaging should enable the physicians not only to diagnose tumors accurately but also to provide 'on the spot' treatment efficiently. It will become comprehensive research tools and technical means \[[@B39]-[@B44]\].

In this study, with the aim of integrating multi-mode targeted imaging and simultaneous therapy into a nanoprobe, we prepared HAI-178 antibody-conjugated FMNPs. Our previous work showed that FMNPs are very stable and have strong fluorescent signals and magnetic intensity, as well good biocompatibility. Using the strong fluorescent signals of the as-prepared nanoprobes, we successfully obtained the targeted fluorescent images of *in vivo* gastric cancer tissues in tumor-bearing nude mice, and using the strong magnetic signals of the as-prepared nanoprobes, we also successfully obtained MR images of *in vivo* gastric cancer tissues in tumor-bearing nude mice. It is confirmed that HAI-178 antibody can inhibit the growth of breast cancer cells \[[@B21]\]; up to date, no report is closely associated with HAI-178 antibody to inhibit growth of gastric cancer. Our results confirmed for the first time that HAI-178 antibody could be used for therapy of *in vivo* gastric cancer.

How to target *in vivo* gastric cancer cells is a key scientific problem \[[@B45]\]. Up to date, no specific gastric cancer biomarkers were reported. Dr. Ni et al. found that α-subunit of ATP synthase exhibited over-expression in breast cancer tissues. In our study, we confirmed that α-subunit of ATP synthase also exhibited over-expression in 94.7% of the gastric cancer specimens, which highly indicate that the α-subunit of ATP synthase may be a potential target for gastric cancer diagnosis and therapy. We also observed that the α-subunit of ATP synthase exhibited over-expression in MGC803 cells, and we used anti-α-subunit of ATP synthase antibody, that is, HAI-178 monoclonal antibody, to conjugate with florescent magnetic nanoparticles. The resultant HAI-178 antibody-conjugated FMNPs successfully realized targeted imaging and simultaneous therapy of *in vivo* gastric cancer, which highly suggests that HAI-178 antibody can target, recognize, and kill *in vivo* cancer cells, specially gastric cancer cells. Thus, the prepared nanoprobes have a great potential in applications such as targeted dual model imaging and selective therapy of early gastric cancer.

Conclusions
===========

We successfully prepared novel HAI-178 antibody-conjugated FMNPs nanoprobes which can be used for targeted two modal imaging of gastric cancer and have an obviously specific targeting ability toward gastric cancer tissues at 2 h of post-injection. In addition, HAI-178 antibody-conjugated FMNPs nanoprobes also exhibited inhibition of growth of gastric cancer, as first reported in this study. The as-prepared nanoprobes also can be used for hyperthermia therapy of gastric cancer under *in vitro* alternating magnetic field irradiation and have great potential in applications such as simultaneous targeted imaging and targeting therapy of clinical gastric cancer in the near future.
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